Featured episode
Immunotherapy for Older Adults With Metastatic cSCC
Featuring David M. Miller, MD, PhD, and Krista M. Rubin, MS, FNP-BC.
View episode →Series overview
This case-based series explores checkpoint inhibitor treatment across advanced and perioperative SCC care. Discussions address treatment selection, recurrence risk, immune-related toxicities, and collaboration among specialties.
Series learning objectives
- Identify high-risk SCC features relevant to recurrence and consideration of immunotherapy.
- Use current efficacy and safety evidence to guide checkpoint inhibitor selection in advanced SCC.
- Plan surveillance and management of immune-related adverse events.
- Coordinate multidisciplinary care for patients with SCC.
Audience
Dermatology, medical oncology, radiation oncology, surgical oncology, and Mohs surgery.
Program support: Provided by Integritas Communications with an educational grant from Regeneron Pharmaceuticals.
See the program website for current accreditation details, faculty disclosures, and credit requirements. The listed expiration date is August 31, 2027.
Program information adapted from NexusMedX. This site represents our opinions only. See our full Disclaimer and Terms of Use Agreement.